您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Staurosporine(AM-2282)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Staurosporine(AM-2282)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Staurosporine(AM-2282)图片
CAS NO:62996-74-1
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
Staurosporine (formerly also known as antibiotic AM-2282; CCRIS 3272; CGP 41251 or STS) is a naturally occuring, potent and non-selective PKC inhibitor with anti-fungal to anti-hypertensive effects. It inhibits PKCα, PKCγ and PKCη with IC50s of 2 nM, 5 nM and 4 nM, respectively. Staurosporine is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus. Staurosporine was discovered to have biological activities ranging from anti-fungal to anti-hypertensive. It less potent to PKCδ (20 nM), PKCε (73 nM) and has little active to PKCζ (1086 nM) in cell-free assays. It also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Staurosporine is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus with anti-fungal to anti-hypertensive effects.
理化性质和储存条件
Molecular Weight (MW)466.53
FormulaC28H26N4O3
CAS No.62996-74-1
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 4 mg/mL (8.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other infoChemical Name: (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-14-one
InChi Key: HKSZLNNOFSGOKW-FYTWVXJKSA-N
InChi Code: InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
SMILES Code: CO[C@@H]1[C@@H](C[C@@H]2N3C4=C(N(C5=CC=CC=C56)[C@@]1(C)O2)C6=C7CNC(C7=C4C8=CC=CC=C83)=O)NC
SynonymsCGP 41251; AM-2282; CGP41251; AM2282; CCRIS 3272; AM 2282; STS; Antibiotic 230; CGP 41251; CGP-41251; Staurosporine; Staurosporin.
实验参考方法
In Vitro

In vitro activity: Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 NM. Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. Staurosporine (1 μM) induces>90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1.


Kinase Assay: Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.


Cell Assay: Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.

In VivoIn the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia.
Animal modelMale Mongolian gerbils or male Wistar rats subjected to transient ischemia
Formulation & DosageDissolved in DMSO and diluted in saline; 10 ng; Stereotaxically administered into the bilateral CAl subfield of the hippocampus
References

Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402; Eur J Biochem. 1995 Nov 15;234(1):317-22; J Cereb Blood Flow Metab. 1990 Sep;10(5):646-53.